Association between epigenomic biomarkers and baseline clinical characteristics in patients with mCRPC treated with rucaparib in TRITON2.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.5086
Abstract: 5086 Background: TRITON2 is a phase 2 study evaluating rucaparib in 277 patients with metastatic castration resistant prostate cancer (mCRPC). PSA has been used to predict radiographic progression free survival (rPFS), overall survival (OS) and… read more here.
Keywords: patients mcrpc; methylation based; methylation; triton2 ... See more keywords